OBI Pharma Sponsors Successful Adagloxad Simolenin (OBI-822) Symposium at ESMO

OBI Pharma is pleased to provide video highlights from the successful company-sponsored symposium that took place at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting in Copenhagen, Denmark, on Monday, October 10, 2016.

The symposium, “Novel Approaches to Active Immunotherapy in Oncology – Targeting Globo Series with Adagloxad Simolenin”, reviewed the data on targeting Globo Series antigens in Metastatic Breast Cancer and other Cancers with the investigational active immunotherapy Adagloxad Simolenin (OBI-822) and examined the future of active immunotherapy in oncology.

The symposium was moderated by Stephen Johnston, MA, PhD, FRCP, Professor of Breast Cancer Medicine and Medical Oncologist at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research in The international faculty were Alice Yu, MD, PhD, Distinguished Chair Professor at the Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital at Linkou in Taiwan; Heather L. McArthur, MD, MPH, Medical Oncologist at Samuel Oschin Comprehensive Cancer Institute in Los Angeles, California and Chiun-Sheng Huang, MD, Professor of Surgery and Director of The Breast Center at the National Taiwan University Hospital and the National Taiwan University College of Medicine.

A video of key symposium highlights can be viewed at the following link:

 width=  width=